GSK plc confirmed it has reached a confidential settlement in the Cantlay/Harper case filed in California state court. “The case, which was set to begin trial on 13 November 2023, will be dismissed. The company has also settled the three remaining breast cancer bellwether cases in California. GSK will be dismissed from these cases, removing all related pre-trial hearings for the company. The settlements reflect the company’s desire to avoid the distraction related to protracted litigation. GSK does not admit any liability in the settlements and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases,” GSK stated in a press release issued today by GSK to the London Stock Exchange.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GSK:
- GlaxoSmithKline (NYSE:GSK) Gains on £2.5B Deal for Shingles Vaccine in China
- Ideaya Biosciences selects Werner Helicase Inhibitor Development DC with GSK
- GSK, Zhifei announce exclusive strategic vaccine partnership in China
- GSK to sell 270M shares in Haleon
- Moderna (NASDAQ:MRNA) Gains on COVID-19 and Flu Shot Combination